InvestorsHub Logo
Followers 1
Posts 465
Boards Moderated 0
Alias Born 09/30/2009

Re: noviceinvestor08 post# 834

Wednesday, 02/23/2011 12:47:03 PM

Wednesday, February 23, 2011 12:47:03 PM

Post# of 6142
"the revised 510k will be refiled this quarter?"

IMHO, it should be filed this quarter but we will still have to wait for approval which may continue to drag on.

The re-file will not really move the PPS much (if at all) but if/when the FDA approves it then we should see movement.

"will the Co issue a PR when refiled?"

I believe that they will...

"what type of bumpin pps we'll see upon refiling?"

Not much if you ask me. The first real bump should be approval of the 510K by the FDA and IMHO the real bump will be the partnership announcement once it is approved.

I see CXM milestones as the following:

1) Approval of 510K
2) Announcement of Partnership for the marketing and distribution once it is approved.
3) Revenue from sales

The things I like about CXM is the potential for a partnership (and/or buy-out) and the chance for some real ongoing revenue by mid 2012 and that right now their share structure is still pretty decent.

The downside is that I do expect some dilution soon as their cash starts running lower. I am personally o.k. with this if it is done in a responsible way but from a market stand-point it will push it to under $0.20 if I had to guess. I'm ready to buy when/if it does but that is a risk that I am willing to take.

Like all Bio's it is risky so do your own DD.

I am playing this for a long term (2012-2013) share price of $10 plus..

GLTA